2023
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesAnal carcinomaClinical practice guidelinesPrimary treatmentPractice guidelinesSquamous cell anal carcinomaCommon histologic formExtrapelvic metastatic diseaseMetastatic anal carcinomaSystemic therapy recommendationsAnal canal cancerCurative-intent treatmentAJCC staging systemNCCN guidelinesPerianal cancerMetastatic diseasePersistent diseaseSystemic therapySurgical treatmentMedical oncologyStaging systemOptimal treatmentClinical evaluationHistologic formsTherapy recommendationsSegmentation of retinal blood vessels by a novel hybrid technique- Principal Component Analysis (PCA) and Contrast Limited Adaptive Histogram Equalization (CLAHE)
Sidhu R, Sachdeva J, Katoch D. Segmentation of retinal blood vessels by a novel hybrid technique- Principal Component Analysis (PCA) and Contrast Limited Adaptive Histogram Equalization (CLAHE). Microvascular Research 2023, 148: 104477. PMID: 36746364, DOI: 10.1016/j.mvr.2023.104477.Peer-Reviewed Original ResearchConceptsDiabetic retinopathyRetinal blood vesselsPost Graduate Institute of Medical Education and ResearchBlood vesselsCotton wool spotsMedical Education and ResearchImages of healthy subjectsDiseases of eyePost Graduate InstitutePersistent diseaseDR patientsComprehensive patient assessmentContrast Limited Adaptive Histogram EqualizationFundus retinal imagesRetinal fundus imagesOphthalmologistsHealthy subjectsNon-disc regionMicro-aneurysmsPGIMER ChandigarhGold standardClinical diagnosisOptic disc boundaryContrast enhancementNormal vessels
2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
Stahl M, Derkach A, Farnoud N, Bewersdorf J, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel M, Cai S, Miles L, Bowman R, Geyer M, Dunbar A, Epstein‐Peterson Z, McGovern E, Schulman J, Glass J, Taylor J, Viny A, Stein E, Getta B, Arcila M, Gao Q, Barker J, Shaffer B, Papadopoulos E, Gyurkocza B, Perales M, Abdel‐Wahab O, Levine R, Giralt S, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman M, Roshal M, Goldberg A. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal Of Hematology 2022, 98: 79-89. PMID: 36251406, PMCID: PMC10080561, DOI: 10.1002/ajh.26757.Peer-Reviewed Original ResearchConceptsMeasurable residual diseaseAcute myeloid leukemiaAllo-SCTInduction chemotherapyPersistent diseaseMyeloid leukemiaAllogeneic stem cell transplantationStem cell transplantationMonosomy 5Residual diseaseDisease clearanceKaryotypic abnormalitiesPrognostic factorsCell transplantationMolecular predictorsMRD clearanceRemissionClinical trialsNext-generation sequencingChemotherapyPatientsMutation patternsTherapyLeukemiaMRD
2020
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. Clinical Cancer Research 2020, 26: 5668-5681. PMID: 32826327, PMCID: PMC7642197, DOI: 10.1158/1078-0432.ccr-19-3685.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCD8-Positive T-LymphocytesFemaleGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMiddle AgedNeoadjuvant TherapyNeoplasm ProteinsNeoplasm Recurrence, LocalPaclitaxelPrognosisProgrammed Cell Death 1 ReceptorProgression-Free SurvivalTreatment OutcomeTriple Negative Breast NeoplasmsTumor MicroenvironmentConceptsTriple-negative breast cancerTumor immune microenvironmentNeoadjuvant chemotherapyOverall survivalBreast cancerPeripheral bloodResidual diseaseMetastatic triple-negative breast cancerEffect of NACImproved long-term outcomesActive antitumor immunityLocal tumor immunityRole of chemotherapyT-cell signatureLong-term outcomesPeripheral T cellsMultiple immune-related genesImmune-related genesNab-paclitaxelImmunologic effectsMicrometastatic diseasePersistent diseaseAntitumor immunityTumor immunityClinical outcomes
2017
Validation of the ureteral diameter ratio for predicting early spontaneous resolution of primary vesicoureteral reflux
Arlen AM, Kirsch AJ, Leong T, Cooper CS. Validation of the ureteral diameter ratio for predicting early spontaneous resolution of primary vesicoureteral reflux. Journal Of Pediatric Urology 2017, 13: 383.e1-383.e6. PMID: 28256423, DOI: 10.1016/j.jpurol.2017.01.012.Peer-Reviewed Original ResearchConceptsPrimary vesicoureteral refluxUreteral diameter ratioVesicoureteral refluxReflux gradeSpontaneous resolutionVUR gradeMultivariable modelUreteral diameterDistal ureteral diameter ratioGrade of VURLargest ureteral diameterPersistent vesicoureteral refluxVesicoureteral reflux gradeGrade of refluxImportant prognostic factorSpontaneous resolution rateValuable prognostic informationL3 vertebral bodyUnit increaseExternal validation studyHighest likelihood ratioVUR timingPersistent diseasePrimary outcomePrognostic factors
2011
Long‐Term Outcome in Patients with Primary Hyperparathyroidism who Underwent Minimally Invasive Parathyroidectomy
Venkat R, Kouniavsky G, Tufano R, Schneider E, Dackiw A, Zeiger M. Long‐Term Outcome in Patients with Primary Hyperparathyroidism who Underwent Minimally Invasive Parathyroidectomy. World Journal Of Surgery 2011, 36: 55-60. PMID: 22089919, DOI: 10.1007/s00268-011-1344-8.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismBiochemical cureInvasive parathyroidectomySymptom resolutionHigh biochemical cure rateLong-term symptom resolutionIntraoperative PTH levelsParathyroid hormone levelsPAS scoresBiochemical cure ratesMean serum calciumLong-term outcomesMean PAS scoreParathyroidectomy assessmentPHPT patientsPTH levelsSestamibi scanPersistent diseaseRecurrent diseaseLong-term evaluationSerum calciumSymptom scoresTerm outcomesPreoperative localizationCure rate
2010
Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management
Chen MK, Doddamane I, Cheng DW. Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Current Opinion In Oncology 2010, 22: 6-10. PMID: 19844179, DOI: 10.1097/cco.0b013e3283339d5d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneMetastatic thyroid cancerThyroid-stimulating hormoneThyroid cancerThyroglobulin levelsWhole body radiation exposureThyroid hormone withdrawalThyroid remnant ablationFurther prospective studiesLong-term outcomesRate of recurrenceSurveillance of patientsThyroid cancer managementBody radiation exposureNegative predictive valueRadioiodine ablationPersistent diseaseRadioiodine treatmentRemnant ablationThyroid remnantsWithdrawal patientsPatients' qualityPatient groupProspective study
2006
Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma
Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clinical Cancer Research 2006, 12: 5809-5816. PMID: 17020988, DOI: 10.1158/1078-0432.ccr-05-2730.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBryostatinsDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMacrolidesMaleMaximum Tolerated DoseMiddle AgedPrognosisSurvival RateVidarabineConceptsChronic lymphocytic leukemiaIndolent lymphomaLymphocytic leukemiaBryostatin 1Dose-limiting toxic eventsTreatment of CLLMonoclonal antibodiesPhase II dosePhase II dosesPhase II studyCD20 monoclonal antibodyII studyPersistent diseaseSuccessive patientsSingle doseContinuous infusionI studiesHematologic malignanciesPreclinical studiesTherapeutic effectFludarabinePatientsPrior treatmentLymphomaPhase I
2004
Asthma: Mechanisms of Disease Persistence and Progression
Cohn L, Elias JA, Chupp GL. Asthma: Mechanisms of Disease Persistence and Progression. Annual Review Of Immunology 2004, 22: 789-815. PMID: 15032597, DOI: 10.1146/annurev.immunol.22.012703.104716.BooksConceptsIL-13Key effector cytokineAnti-inflammatory therapyIL-13 productionProduction of chemokinesProgression of diseaseAirway fibrosisAllergic asthmaAirway remodelingEffector cytokinesEosinophilic inflammationPersistent diseaseTh2 cytokinesEpithelial damageDisease progressionInflammatory responseTh2 cellsMucus productionSmooth muscleBronchial airwaysMatrix metalloproteinasesAnimal dataAsthmaDisease persistenceInflammationThe MACIS Score Predicts the Clinical Course of Papillary Thyroid Carcinoma in Children and Adolescents
Powers PA, Dinauer CA, Tuttle RM, Francis GL. The MACIS Score Predicts the Clinical Course of Papillary Thyroid Carcinoma in Children and Adolescents. Journal Of Pediatric Endocrinology And Metabolism 2004, 17: 339-344. PMID: 15112910, DOI: 10.1515/jpem.2004.17.3.339.Peer-Reviewed Original Research
2003
Treatment of Recurrent Papillary Thyroid Carcinoma in Children and Adolescents
Powers PA, Dinauer CA, Tuttle RM, Francis GL. Treatment of Recurrent Papillary Thyroid Carcinoma in Children and Adolescents. Journal Of Pediatric Endocrinology And Metabolism 2003, 16: 1033-1040. PMID: 14513881, DOI: 10.1515/jpem.2003.16.7.1033.Peer-Reviewed Original ResearchConceptsRecurrent papillary thyroid carcinomaPapillary thyroid carcinomaThyroid carcinomaYears of ageThird remissionCervical nodesPersistent diseaseClinical coursePoor prognosisSecond recurrenceHigh mortalityRemissionChildrenCarcinomaRecurrenceMortalityTreatmentAdultsPrevious dataPatientsPrognosisDiseaseTumor Size and Extent of Disease at Diagnosis Predict the Response to Initial Therapy for Papillary Thyroid Carcinoma in Children and Adolescents
Powers PA, Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Francis GL. Tumor Size and Extent of Disease at Diagnosis Predict the Response to Initial Therapy for Papillary Thyroid Carcinoma in Children and Adolescents. Journal Of Pediatric Endocrinology And Metabolism 2003, 16: 693-702. PMID: 12880118, DOI: 10.1515/jpem.2003.16.5.693.Peer-Reviewed Original ResearchConceptsPapillary thyroid carcinomaExtent of diseaseLarger tumor sizeTumor sizeExtensive diseaseInitial treatmentThyroid carcinomaRadioactive iodine treatmentClass IV patientsInitial therapyFirst remissionIV patientsPersistent diseaseMultifocal diseasePatientsClass IIIRemissionClass IIIodine treatmentDiseaseClass IDiagnosisTreatmentCarcinomaChildren
1998
Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Wilson L, Kacinski B, Jones G. Local Superficial Radiotherapy in the Management of Minimal Stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides). International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 109-115. PMID: 9422565, DOI: 10.1016/s0360-3016(97)00553-1.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaStage IA mycosis fungoidesT-cell lymphomaAdjuvant therapyLocal controlMycosis fungoidesSuperficial radiationSuperficial radiotherapyDistant skin sitesMedian fraction numberMedian surface doseComplete response rateExcellent local controlDry desquamationPrior therapyHematologic toxicityPrior radiationDistant failurePersistent diseaseMedian ageCutaneous malignanciesPathologic documentationSurface doseMild erythemaPatients
1995
Report of Eight Cases and Review of the Literature
Hasserjian R, Klimstra D, Rosai J. Report of Eight Cases and Review of the Literature. The American Journal Of Surgical Pathology 1995, 19: 835-841. PMID: 7793482, DOI: 10.1097/00000478-199507000-00012.Peer-Reviewed Original ResearchConceptsClear-cell featuresThymic carcinomaClear-cellCases of thymic carcinomaHigh-grade thymic carcinomasMetastatic clear-cell carcinomaSheet-like growth patternHigh-molecular-weight keratinPrimary thymic carcinomaDead of diseaseClear-cell carcinomaEpithelial membrane antigenAggressive clinical behaviorClear-cell neoplasmsMediastinal seminomaPlacental alkaline phosphataseParathyroid carcinomaPersistent diseaseMembrane antigenClinical behaviorTumor cellsDifferential diagnosisFollow-upCarcinomaNuclear featuresBazex syndrome: acrokeratosis paraneoplastica.
Bolognia J. Bazex syndrome: acrokeratosis paraneoplastica. Seminars In Cutaneous Medicine And Surgery 1995, 14: 84-9. PMID: 7640201, DOI: 10.1016/s1085-5629(05)80002-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcrokeratosis paraneoplasticaSkin lesionsUnderlying neoplasmBazex syndromeAdequate clinical descriptionUpper aerodigestive tractSquamous cell carcinomaCutaneous manifestationsPersistent diseaseCutaneous signsAerodigestive tractParaneoplastic naturePsoriasiform lesionsCell carcinomaClinical descriptionLesionsPatientsNeoplasmsDiagnosisSyndromeTumorsDiseaseCarcinomaRecurrenceMalignancylocalization Studies in Patients with Hyperparathyroidism
Mitchell B, Kinder B, Merrell R. localization Studies in Patients with Hyperparathyroidism. 1995, 75: 483-498. PMID: 7747254, DOI: 10.1016/s0039-6109(16)46635-1.Peer-Reviewed Original ResearchConceptsMultiple gland diseasePrevious neck surgeryCervical explorationSuspicious glandsParathyroid explorationPersistent diseasePreoperative localizationMinimal morbiditySestamibi SPECTHigh success rateNeck surgeryInvasive proceduresGland diseaseParathyroid anatomySurgical handsPatientsSkilled surgical handsSuccess rateHyperparathyroidismComplementary testsDiseaseGlandLimited sensitivityLocalization studiesMorbidity
1991
Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases.
Stovall T, Ling F, Gray L, Carson S, Buster J. Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases. Obstetrics And Gynecology 1991, 77: 749-53. PMID: 2014090.Peer-Reviewed Original ResearchConceptsUnruptured ectopic pregnancyEctopic pregnancyConservative surgical proceduresHCG titerPatient nosPrimary therapySurgical proceduresSide effectsPrevious ectopic pregnancyRecurrent ectopic pregnancyIdentifiable risk factorsOngoing clinical trialsCardiac activityTubal pregnancyPersistent diseaseFourth doseMedical therapyMethotrexate treatmentOutpatient protocolInvolved sideTubal patencyRisk factorsClinical trialsPregnancyPatients
1977
Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients.
Anderson T, Bender R, Rosenoff S, Brereton H, Chabner B, DeVita V, Hubbard S, Young R. Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients. Journal Of The National Cancer Institute 1977, 61: 1017-22. PMID: 143345.Peer-Reviewed Original ResearchConceptsHodgkin's lymphoma patientsPercutaneous liver biopsyLymphoma patientsHepatic involvementLiver biopsyComplete clinical remissionLow morbidity rateActive diseaseClinical relapseClinical remissionIntensive chemotherapyPersistent diseaseLess morbidityMorbidity rateHodgkin's lymphomaPatientsTherapeutic efficacyBiopsyRelapseLymphomaDiseaseInvolvementLaparotomyRemissionMorbidity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply